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A B S T R A C T
Purpose: Verapamil, a voltage-gated calcium channel blocker, has been occasionally reported to have
some effect on reducing seizure frequency in drug-resistant epilepsy or status epilepticus. We aimed to
investigate the efﬁcacy of verapamil as add-on treatment in children with drug-resistant epilepsy.
Methods: Seven children with drug-resistant structural-metabolic, unknown or genetic (e.g., Dravet
syndrome [DS]) epilepsy received verapamil as an add-on drug to baseline antiepileptic therapy.
Verapamil was slowly introduced at the dosage of 1 mg/kg/day and titrated up to 1.5 mg/kg/day. After
completing the titration period, patients entered a 14-month maintenance period and were followed up
at 3, 8, and 14 months. Heart monitoring was performed at baseline and at each follow-up. The primary
outcome measure was the response of seizures to verapamil.
Results: Three subjects with genetically determined DS showed a partial (reduction of 50–99%) response
for all types of seizures. A patient with DS without known mutation showed a partial control of all types
of seizures in the ﬁrst 13 months; then seizures worsened and verapamil was suspended. Two patients
with structural epilepsy and one with Lennox–Gastaut syndrome showed no improvement. Any side
effects were recorded.
Conclusions: Add-on treatment with verapamil seems to have some effect in controlling seizures in
patients with genetically determined DS. Our observations justify further research on the relationship
between calcium channels, calcium channel blockers, and channelopathies.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Resistance to antiepileptic drugs (AEDs) is one of the most
common unsolved issues in the treatment of paediatric- and adult-
onset epilepsy. It is estimated that up to 26% of epilepsy can show
drug resistance, thus leading to neuropsychiatric and social
impairment, lower quality of life, greater morbidity, and a higher
risk of death.1,2 Although several new AEDs have been developed in
the recent years, epilepsy remains resistant to drug therapy in
about one-third of patients, thus encouraging the discovery of
drugs that act on the mechanisms underlying pharmacoresistance.
Genetic predisposition, abnormal drug metabolism, the failure of
drugs to reach their targets, and changes in drug targets in the* Corresponding author at: Child Neurology Division, Department of Pediatrics,
Umberto I Hospital, Sapienza University of Rome, Viale Regina Elena 324, 00161
Rome, Italy. Tel.: +39 0649979311.
E-mail address: childneurology.sapienzaroma@live.it (A. Spalice).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.09.009brain have all been considered to be involved in determining
response to AEDs.3
Multidrug transporters (MDTs) are likely to play a role in the
pathogenesis of drug resistance in epilepsy, acting at the level of
the blood–brain barrier (BBB) by returning AEDs to the blood
vessels and lowering brain penetration and concentration.4,5
Among the MDTs, the P-glycoprotein (Pgp), also known as ATP-
binding cassette sub-family B member 1 (ABCB1) or multidrug
resistance protein 1 (MDR1), is a drug efﬂux transporter that limits
the access of numerous AEDs to their site of action in the brain.6,7
Verapamil, a voltage-gated calcium channel blocker that can also
inhibit Pgp at the BBB level, has been used with encouraging results
in epileptic patients suffering from drug-resistant epilepsy
syndromes8 or status epilepticus.9–12 The main hypotheses on
this topic are that verapamil may increase the brain inﬂux of AEDs
by blocking Pgp and may also maintain resting membrane
potentials by modulating the abnormal calcium inﬂuxes in
neurons, which are considered to be responsible for membrane
hyper-excitability, yielding seizure disorders.8 The aim of thisvier Ltd. All rights reserved.
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treatment in a group of children with drug-resistant epilepsy.
2. Methods
Seven patients with structural-metabolic (two), unknown
(two), or genetic (three) drug-resistant epilepsy were recruited
in a prospective, add-on, open-label study from the Paediatric
Neurology Unit of Sapienza University of Rome, Italy and an
epilepsy centre of Dianalund, Denmark. All selected patients had
the following features: (1) drug-resistant epilepsy despite the use
of three previous AEDs, alone or in combination; (2) the use of at
least two AEDs, but no more than four; (3) more than three seizures
per month in the last 6 months; and (4) written informed consent
from parents and/or caregivers, and their complete helpfulness in
administering the study drug according to the provided schedule.
Parents/caregivers were comprehensively informed about the
possible adverse events of verapamil, and were educated to
immediately refer to us in case of any side effect. They were also
asked to correctly complete a diary recording the frequency, type,
and duration of seizures. Seizures and epilepsy aetiology were
classiﬁed according to ILAE terminology.13
The study comprised the following phases:
1. Baseline phase. Past medical history was carefully collected; all
the patients underwent full neurological examination, brain
magnetic resonance imaging (MRI), and video-electroencepha-
logram (EEG) recording. Heart monitoring (i.e., blood pressure,
electrocardiogram [ECG], and paediatric cardiologist evaluation)
and blood examinations (i.e., routine blood cell counts and
biochemistry, AED level) were undertaken for each patient.
2. Titration phase. In all children, verapamil was slowly introduced
at the dosage of 1 mg/kg/day and titrated up to 1.5 mg/kg/day in
a period of 14 days. Verapamil was administered not later than
6 p.m. in order to avoid physiological bradycardia. We kept in
mind that if baseline therapy comprised phenobarbital or
phenytoin, blood verapamil levels could be reduced due to
enzymatic induction, and that verapamil could increase blood
levels of carbamazepine. Patients were followed up weekly
during the titration phase.
3. Follow-up phase. After completing the titration period, patients
entered a 14-month maintenance period and were followed up
at 3, 8, and 14 months, if no adverse effects or complications
occurred. In case of side effects, complication, or worsening of
seizure, treatment with verapamil was promptly suspended. At
each follow-up, patients underwent physical and neurological
examination, ECG, blood chemistry, AED dosages, and EEG.
The primary outcome measure was the response of seizures to
verapamil. It was classiﬁed as ‘seizure freedom’ in case of seizure
disappearance (100% responders), ‘partial response’ if the reduc-
tion was 50–99%, ‘no response’ if seizure reduction was <50%, and
‘seizure worsening’ if seizure frequency and/or severity increased.
We also evaluated interictal EEG changes (improved, worsened, or
unmodiﬁed interictal epileptic activity). Safety was evaluated by
recording every type of adverse event, taking into consideration
that the most important side effects relating to verapamil are
headache, arterial hypotension, vertigo, constipation, itch sensa-
tion, and kidney or liver failure.
3. Results
The main patient data are summarised in Table 1. Seven
patients (three males, four females; age range: 4.2–18 years; mean
age: 11 years) were enrolled in this study. Two patients (1 and 2,
Table 1) have been previously reported.8 Four cases had a diagnosisof the Dravet syndrome (DS) spectrum, including one severe
myoclonic epilepsy of infancy (SMEI) patient (patient 1, Table 1)
without mutation of the sodium channel alpha-1 subunit (SCN1A)
and three SMEI patients (2–4) with mutation of the SCN1A. One
patient (number 5) had a diagnosis of Lennox–Gastaut syndrome
(LGS); SCN1A analysis did not reveal anomaly in this patient. In
two cases, the diagnosis of symptomatic epilepsy was achieved,
including a case (patient 6) of semilobar holoprosencephaly with
agenesis of the corpus callosum and a case (patient 7) of
periventricular leukomalacia with diffuse cortical atrophy as a
consequence of hypoxic-ischaemic encephalopathy.
Seizure semiology was classiﬁed as myoclonic in six patients,
febrile in four patients, generalised tonic-clonic, atypical absence,
and atonic in three patients, reﬂex, generalised tonic, simple
partial, hemiclonic, and complex partial with secondary generali-
sation in two patients, and gelastic in one patient; four patients had
experienced status epilepticus. All of the patients showed more
than one type of seizure, with at least four different semiologies for
each subject. At baseline, all patients presented with daily (1–10)
seizures and received at least two other AEDs, used in various
combinations according to the type of epilepsy. Moderate-to-
severe developmental delay was present in all the subjects.
Blood examinations obtained during verapamil administration
revealed normal results for erythrocyte and leukocyte counts,
amylase, transaminases, gamma-glutamyl transpeptidase, and
blood urea nitrogen. Verapamil did not alter the blood levels of
the associated AEDs, except for a slight increase (20% from baseline
blood level) of phenytoin level in one case (patient 1). No
interactions with other drugs (e.g., antipyretics, antibiotics) or any
side effects were recorded.
The patient with DS without mutation of the SCN1A or
protocadherin 19 (PCDH19) gene showed a partial control of all
types of seizures in the ﬁrst 13 months; then seizures worsened
and verapamil was tapered and suspended. The three subjects with
DS and SCN1A mutation showed a partial response for all types of
seizures; additionally, an improvement in cognitive performances
(such as attention, concentration, participation, and socialisation)
was reported by parents (and veriﬁed by us during each follow-up),
but we did not verify it with appropriate tests. A partial control of
generalised tonic-clonic seizures was observed in the boy with LGS
for a brief period; however, seizures quickly returned at the
baseline frequency. Finally, patients with symptomatic epilepsy
showed no effects or a brief improvement with subsequent
worsening, after which verapamil administration was suspended.
Improvement in interictal epileptic activity on EEG was clearly
observed only in one case (patient 2): it consisted of an almost
complete disappearance of diffuse spikes and spike-and-wave
complexes during sleep and wakefulness, with rare spikes in the
right frontotemporal region.
4. Discussion
We report here on seven children with drug-resistant epilepsy
who received verapamil as add-on therapy, with the goal of
reducing seizures by an inhibition of Pgp function at the level of the
BBB, in order to improve the brain inﬂow of AEDs. Experimental
studies in animal models suggested this strategy.14,15 The Pgp is a
MDT that acts at the level of the BBB and is postulated to be
involved in the pathogenesis of drug resistance in epileptic
subjects by sending the AEDs back in the lumen of brain vessels,
forbidding their inﬂux and action.16,17 Several AEDs, or their
metabolites, are known to be substrates of the Pgp (i.e.,
carbamazepine-epoxide, felbamate, gabapentin, lamotrigine, leve-
tiracetam, phenytoin, phenobarbital, and topiramate).5,6 The
hypothesis that the Pgp may be involved in mechanisms of drug
resistance is derived from investigations in rodent models and
Table 1
Main features of the reported patients.
Patient (age, sex) Epilepsy type Genetic
analysis
Seizure type and
frequency (be-
fore
verapamil)
Developmental
delay
Brain MRI Seizure
(under verapamil)
Inter-ictal
EEG (under
verapamil)
Cognitive function
(under verapamil)
Side
effects
AEDs associated
with verapamil
1 (14 years, F) DS SCN1A and
PCDH19
negative
FS (at onset); RS
and M (25–30
daily); PS
(monthly);
GTCS and SE
(bimonthly)
Moderate N Partial control of all
types of seizures in
the ﬁrst 13 months
(reduction of 90%);
then worsening
and suspension
Unmodiﬁed No effects No VPA, TPMc, PHTc, ETS
2 (8 years, F) DS SCN1A
mutation
c.716C>T
FS (at onset); M
(15–20 daily);
GCTS, PS and SE
(monthly)
Severe N Partial control of M,
GTCS, PS (90%).
Disappearance of
SE
Improvement Improvementa No PBc, LTGc, TPMc
3 (4 years
2 months, M)b
DS SCN1A
mutation
c.3972insT
FS (at onset); H
(2 per month),
At and MA (60–
100 daily)
Moderate N Partial control of all
types of seizures
(reduction of 60%)
Unmodiﬁed Improvementa No LEVc, VPA
4 (4 years
2 months, M)b
DS SCN1A
mutation
c.3972insT
FS (at onset), H
(1 monthly), At
and MA (100–
150 daily)
Moderate N Partial control of all
types of seizures
(reduction of 60%)
Unmodiﬁed Improvementa No LEVc, VPA
5 (18, M) LGS SCN1A negative T (1–2 daily); At
and A (8–10
weekly); GTCS
(2–4 monthly)
Severe N Partial control of
GTCS in the ﬁrst 2
months (0–1
monthly); then
return at baseline
Unmodiﬁed No effects No LEVc, VPA
6 (15 years, F) Symptomatic
epilepsy
None performed M and RS (6–7
daily); CPS with
SG and T (1–2
monthly)
Severe Periventricular
leukomalacia
and diffuse
cortical atrophy
No effects Unmodiﬁed No effects No ZNS, LTGc, CLZ
7 (14 years, F) Symptomatic
epilepsy
None performed M (8–10 daily);
CPS with SG (2–
3 per month); T
and G (monthly)
Severe Semilobar holoprosencephaly;
corpus callosum
agenesis
Partial control of
M in the ﬁrst 3
months (0–3
daily); then
worsening of all
seizures and
suspension
Unmodiﬁed No effects No LCS, LTGc, PBc
List of abbreviations: DS, Dravet syndrome; SCN1A, sodium channel alpha-1 subunit; PCDH19, protocadherin 19; GTCS, generalised tonic clonic seizures; M, myoclonic seizures; H, hemiclonic seizure; MA, myoclonic-atonic seizure;
PS, partial seizure; T, tonic seizures; G, gelastic seizures; RS, reﬂex seizures; SE, status epilepticus; At, atonic seizures; A, atypical absence seizures; CPS, complex partial seizure; SG, secondarily generalisation; N, normal; VPA,
valproic acid; PB, phenobarbital; LTG, lamotrigine; TPM, topiramate; LEV, levetiracetam; PHT, phenytoin; ETS, etosuximide; ZNS, zonisamide; LCS, lacosamide; CLZ, clobazam.
a Improvement of cognitive functions consisted of higher attention, concentration, participation and socialisation for all the children.
b Patients 3 and 4 are a couple of identical twins.
c AEDs that are known to be substrate of Pgp.
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thelial Pgp expression in limbic regions ipsilateral to the epileptic
focus compared with drug-responsive rats18; post-surgery or post-
mortem tissues of pharmacoresistant patients have revealed that
chronic epilepsy is associated with inﬂammation and enhanced
Pgp (without affecting other transporters) at the BBB level.19,20
This overexpression leads to a reduced brain concentration of Pgp
substrates,15 which can be restored after Pgp inhibition.14
Furthermore, it has been demonstrated that seizure activity can
transiently increase Pgp expression in brain capillary endothelial
cells of epileptic dogs.21 However, a recent study of idiopathic
drug-resistant canine epilepsy failed to demonstrate the efﬁcacy of
verapamil add-on treatment in improving seizure control and
increasing phenobarbital concentration in the cerebrospinal ﬂuid;
verapamil treatment was discontinued in all the dogs due to side
effects (e.g., bradycardia and arterial hypotension) or an increase in
seizure frequency.16
Studies on humans are limited to a few case reports. Firstly,
Summers and colleagues described successful treatment with
verapamil in a 24-year-old woman with idiopathic intractable
complex partial seizures.9 Successively, some of us used verapamil
in a case of refractory status epilepticus and supra-ventricular
tachycardia10 and in two patients with SMEI (patients 1 and 2 in
Table 1).8 Schmitt et al. reported on a 20-year-old woman with
idiopathic frontal lobe epilepsy and recurrent status epilepticus,
and Pirker and Baumgartner described a case of structural focal
status epilepticus: both patients showed a favourable response to
add-on treatment with verapamil, with the cessation of status
epilepticus.11,12 Recently, the relationship between pharmacore-
sistance and Pgp overexpression has been assessed in vivo for the
ﬁrst time, by using positron emission tomography (PET) with the
Pgp substrate (R)-[11C]verapamil in patients with temporal lobe
epilepsy.22 Previously, other authors failed to detect statistically
signiﬁcant differences by using the same technique.23 Feldmann
and colleagues discovered reduced uptake of Pgp substrate in the
temporal lobe of drug-resistant patients (i.e., indicating a higher
Pgp baseline activity) compared with seizure-free subjects, and
attenuated increase of substrate after Pgp inhibition by means of
tariquidar in treatment-resistant patients compared with healthy
controls. This in vivo result was conﬁrmed by ex vivo Pgp
measurement in temporal lobe tissues of ﬁve patients who
underwent surgery.22
In this add-on open-label study, all the reported patients
received common AEDs in various combinations according to
clinical features; each patient received at least one AED that is
known to be a substrate of Pgp at the level of the BBB (see
Table 1).6–9 Cardiac side effects of verapamil were not observed in
this study; side effects limited long-lasting treatment in previous
studies in humans and animal models.10,16 Treatment with
verapamil gave encouraging results in patients with DS but not
in patients with LGS or structural epilepsy. In one case of SCN1A-
and PCDH19-negative DS, improvement in myoclonic, partial, and
generalised seizures was limited to a period of 13 months, when
seizures worsened and verapamil was discontinued.8 At present,
this girl, still followed-up in our centre, is under therapy with
multiple AEDs, and her seizures remain drug-resistant. Patients
with genetically conﬁrmed DS showed a favourable response in
terms of control of seizures and cognitive performances, although a
standardised scale was not used for measuring improvements in
behaviour. Notably, these three subjects differ from case 1 in the
presence of a mutation in the SCN1A, which is known to be
responsible for 80% of DS.
DS is a drug-resistant epileptic encephalopathy characterised
by recurrent and long-lasting febrile seizures, afebrile seizures
(e.g., myoclonic, complex partial, and atypical absence), the
regression of cognitive function, ataxia, and pyramidal signs.24 Ithas been shown that both gain- and loss-of-function SCN1A
mutations may alter the neuronal Na+ current and brain
excitability, resulting in a ﬁnal phenotype that is DS.25
It is known that neuronal membrane equilibrium is the result of
different ion ﬂows (sodium, potassium, and calcium) that
contribute to the maintenance of the state of membrane
polarisation and neuronal excitability.26,27 In our previous work,
we speculated that verapamil may also act by: (a) diminishing Ca++
entry into the cell; (b) activating potassium–calcium channel
sensitive with direct binding of intracellular Ca++; and (c)
counteracting the action of persisting current induced by non-
functional SCN1A via the diminution of intracellular Ca++ with ﬁnal
membrane repolarisation.7 In other words, verapamil, beside its
effect on Pgp activity, may also be effective in restoring ionic
membrane equilibrium.
Our good results in terms of seizure control in patients with
DS and SCN1A mutations might be related to these actions. In
contrast, the improvement in seizure control with subsequent
worsening in the patient with DS without SCN1A anomaly and
with LGS might only depend on temporary inhibition of the Pgp,
as we previously speculated.8 Furthermore, we cannot exclude
that the partial or negative results observed in these two
patients, as in the subjects affected by structural epilepsy, might
be related to unknown (drug-resistant) epilepsy-causing mech-
anisms different from Pgp action or Ca++ ﬂows towards cellular
membranes.3 Unfortunately, we did not quantify the impact of
Pgp on the drug resistance observed in our patients (in vivo, by
performing a PET scan with the Pgp substrate (R)-[11C]verapamil
before [and after] the treatment with verapamil, and ex vivo by
analysing the ATP binding cassette 1 (ABC1) gene C3435T
polymorphism28 or studying the Pgp in surgical tissues). To
answer the many questions on the relationship between Pgp
expression and antiepileptic drug resistance29 is beyond the
aims of this study.
In conclusion, treatment with verapamil seems to have some
effect in controlling seizures in patients with DS and SCN1A
mutations, while it was less effective in patients with DS without
SCN1A mutations and LGS. No effect was noticed in patients with
structural epilepsy. Inhibition of the Pgp and restoring of neuronal
membrane ion equilibrium might explain the effectiveness of
verapamil in treating SCN1A-mutated DS patients. The main limits
of this study are the small number of enrolled subjects, which did
not allow statistical analysis, and the lack of a blinded and placebo-
controlled design. Our observations justify further research on the
relationship between calcium channels, calcium channel blockers,
and channelopathies. The recent application of PET with the Pgp
substrate (R)-[11C]verapamil will be useful for novel combined
imaging and pharmacological trials in epileptic treatment-resis-
tant patients.
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